Dr. Odejide is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
450 Brookline Avenue
Boston, MA 02215Phone+1 617-632-3470Fax+1 617-632-5175- Is this information wrong?
Summary
- Dr. Oreofe Odejide is an oncologist in Boston, MA and is affiliated with multiple hospitals in the area, including Dana-Farber Cancer Institute and Brigham and Women's Hospital. She received her medical degree from Howard University College of Medicine and has been in practice 9 years. She specializes in hematologic oncology.
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2011 - 2014- Brigham and Women's HospitalResidency, Internal Medicine, 2008 - 2011
Howard University College of MedicineClass of 2008
Harvard T.H Chan School of Public HealthMPH, Clinical Effectiveness
Certifications & Licensure
MA State Medical License 2011 - 2025
ME State Medical License 2022 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- UPLYFT For Lymphoma Survivors Start of enrollment: 2022 Feb 08
Roles: Principal Investigator, Contact
- Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia Start of enrollment: 2022 Jun 01
Roles: Contact
- Home Transfusion for HEME Start of enrollment: 2024 Apr 30
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- Depression in patients with hematologic malignancies: The current landscape and future directions.Thomas M Kuczmarski, Lizabeth Roemer, Oreofe O Odejide> ;Blood Reviews. 2024 May 1
- A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma.Reid W Merryman, Robert A Redd, Arnold S Freedman, Inhye E Ahn, Jennifer R Brown, Jennifer L Crombie, Matthew S Davids, David C Fisher, Eric D Jacobsen, Austin I Kim, ...> ;Annals of Hematology. 2024 Jan 1
- Perspectives on Transfusions for Hospice Patients With Blood Cancers: A Survey of Hospice Providers.Helen P Knight, Caitlin Brennan, Susan Lysaght Hurley, Anna J Tidswell, Melissa D Aldridge, Kimberly S Johnson, Edo Banach, James A Tulsky, Gregory A Abel, Oreofe O Od...> ;Journal of Pain and Symptom Management. 2024 Jan 1
- Join now to see all
Abstracts/Posters
- Utilization and Early Discontinuation of First-Line Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology Setting in the United St...Oreofe O. Odejide, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- Moving Forward When It Is Time to StopASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019
- PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Pha...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Study Finds Fewer Blood Cancer Patients Get Hospice CareMay 22nd, 2017
Opdivo Could Boost Outcomes for People Battling Hodgkin LymphomaJune 7th, 2023- Genetically Modifying T-cells Cuts Blood Cancer Progression by 74%, Trial FindsJune 6th, 2023
Professional Memberships
- Member
Hospital Affiliations
Dana-Farber Cancer InstituteBoston, Massachusetts
Brigham and Women's HospitalBoston, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
